Bayer stock eases below 49 euros as Q2 2026 figures and debt targets shape expectations

Published on 09/03/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock is trading slightly lower on Xetra as investors weigh the stronger Q2 2026 earnings, updated debt guidance and the latest analyst targets for the German healthcare and crop science group.

Makrofotografie von weißen runden Tabletten in extremer Nahaufnahme — Bayer AG (DE000BAY0017): Makroaufnahme weißer runder Tabletten mit scharfer Tiefenschärfe und feiner Oberflächentextur, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) stock was recently quoted at 48.78 euros on Xetra on September 3, 2026, around 0.8 percent below the opening level of 49.50 euros as investors continue to digest the company’s second-quarter 2026 figures and updated balance sheet targets for the year according to finanzen.ch.

Q2 2026 earnings and guidance in focus

According to an overview of Bayer’s latest financial guidance reported by Ad hoc News, the company is targeting full-year 2026 revenue between 44.7 billion and 47.0 billion EUR, with core earnings per share forecast in a range of 4.10 to 4.80 EUR.

The same report notes that after the second quarter of 2026 Bayer reduced its outlook for year-end net financial debt from a previously guided 32.0–33.0 billion EUR to 29.0–30.0 billion EUR, underscoring management’s focus on deleveraging alongside operational improvements.

Segment trends and quantified comparisons

In its Crop Science division, Bayer achieved a 30.2 percent improvement in adjusted earnings in the second quarter of 2026 compared with the prior-year period, despite continued pricing pressure in agrochemicals, according to Ad hoc News.

Meanwhile, within the pharmaceuticals segment, adjusted earnings slipped by 3.6 percent in the second quarter of 2026 versus the previous year, but the prostate cancer therapy Nubeqa generated quarterly sales of 820 million EUR and remains a key growth driver, the same source reports.

Go deeper

More on Bayer shares and fundamentals

Investors can find additional background on Bayer stock, its latest earnings releases and current guidance in the topic overview and on the company’s Investor Relations page.

All articles on DE000BAY0017 Investor Relations

Analyst view and trading range

A recent analyst roundup cited by Ad hoc News highlights that several major banks have assigned positive ratings on Bayer in the wake of the second-quarter 2026 results, with institutions such as Deutsche Bank, UBS, JPMorgan Chase and Goldman Sachs favoring Buy or Overweight stances while Jefferies remains more cautious with a Hold recommendation.

The same overview indicates that UBS issued a fresh update earlier in the week referenced in the article, reaffirming a Buy rating and setting a price target of 62.00 EUR for Bayer shares, implying upside from the current trading range if the company delivers on its debt reduction and earnings plans.

Representative product in crop science

Bayer’s Crop Science business has been highlighted as a core pillar of its growth strategy, with the company aiming to accelerate launches and ultimately bring around ten new agrochemical and seed blockbusters to market over the coming years, as reported by Indian Chemical News.

Stock level on German trading venues

On September 3, 2026, market data compiled by finanzen.ch showed Bayer shares at 48.78 EUR in the Xetra session at 12:29, down 0.8 percent from the opening print of 49.50 EUR, after touching an intraday low of 48.62 EUR.